Cliff Asness's PTGX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 6,954 shares of Protagonist Therapeutics, Inc. (PTGX) worth $607,362, representing 0.00% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in PTGX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2022, adding 114,688 shares. Largest reduction occurred in Q1 2025, reducing 110,010 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1,616 | Reduce 18.86% | 6,954 | $87.34 |
| Q3 2025 | -8,839 | Reduce 50.77% | 8,570 | $66.43 |
| Q2 2025 | -22,678 | Reduce 56.57% | 17,409 | $55.27 |
| Q1 2025 | -110,010 | Reduce 73.29% | 40,087 | $48.36 |
| Q4 2024 | +12,926 | Add 9.42% | 150,097 | $38.60 |
| Q3 2024 | +112,116 | Add 447.48% | 137,171 | $45.00 |
| Q2 2024 | -55,952 | Reduce 69.07% | 25,055 | $34.65 |
| Q1 2024 | +71,665 | Add 767.13% | 81,007 | $28.93 |
| Q4 2023 | -1,124 | Reduce 10.74% | 9,342 | $22.93 |
| Q3 2023 | -653 | Reduce 5.87% | 10,466 | $16.68 |
| Q2 2023 | +11,119 | New Buy | 11,119 | $27.62 |
| Q1 2023 | -40,970 | Sold Out | 0 | $0.00 |
| Q4 2022 | -73,718 | Reduce 64.28% | 40,970 | $10.91 |
| Q3 2022 | +114,688 | New Buy | 114,688 | $8.43 |
| Q1 2022 | -15,177 | Sold Out | 0 | $0.00 |
| Q4 2021 | -26,500 | Reduce 63.58% | 15,177 | $34.20 |
| Q3 2021 | +15,069 | Add 56.63% | 41,677 | $17.73 |
| Q2 2021 | -3,779 | Reduce 12.44% | 26,608 | $44.87 |
| Q1 2021 | +6,964 | Add 29.73% | 30,387 | $25.90 |
| Q4 2020 | +623 | Add 2.73% | 23,423 | $20.15 |
| Q3 2020 | +22,800 | New Buy | 22,800 | $19.56 |
| Q2 2020 | -11,347 | Sold Out | 0 | $0.00 |
| Q1 2020 | -11,340 | Reduce 49.98% | 11,347 | $7.05 |
| Q3 2019 | +22,687 | New Buy | 22,687 | $11.99 |
Cliff Asness's Protagonist Therapeutics Investment FAQs
Cliff Asness first purchased Protagonist Therapeutics, Inc. (PTGX) in Q3 2019, acquiring 22,687 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Protagonist Therapeutics, Inc. (PTGX) for 25 quarters since Q3 2019.
Cliff Asness's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q3 2022, adding 114,688 shares worth $967,000.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 6,954 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $607,362.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 150,097 shares, as reported at the end of Q4 2024.